Liposomal bupivacaine plus bupivacaine

Phase 3Small molecule

HHuazhong University of Science and Technology

Liposomal bupivacaine plus bupivacaine is one of 34 small molecule programs targeting Hemorrhoid. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HemorrhoidActive, not recruiting

Video-Assisted Thoracoscopic Surgery (VATS)Recruiting

Video-Assisted Thoracoscopic SurgeryRecruiting

Liposomal BupivacaineRecruiting

Hip ArthroplastyRecruiting

HemorrhoidPreclinical

Active, not recruiting

Video-Assisted Thoracoscopic Surgery (VATS)Preclinical

Recruiting

Video-Assisted Thoracoscopic SurgeryPreclinical

Recruiting

Liposomal BupivacainePreclinical

Recruiting

Hip ArthroplastyPhase 3

Recruiting

Competition

Competitive Landscape

27 competitors in Hemorrhoid

#DrugCompanyPhaseTrials

Isordil

AstraZeneca

Approved

—2

Botox

RRevance Therapeutics, Inc.

Approved

2 3

Ketalar

AAultman Health Foundation

Approved

1 4

Marcaine

IInnocoll

Approved

1 5

Cardizem

BBausch Health Americas, Inc.

Approved

1 6

Nitrostat

VViatris Specialty LLC

Approved

1 7

Kenalog

BBassett Healthcare

Approved

—8

Neo-Synephrine

EExela Pharma Sciences, LLC.

Celestone

Decadron

AAspen Global Incorporated

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

N/ARecruiting

Hemorrhoid

NCT07442539

N/ARecruiting

Liposomal Bupivacaine

NCT07458256

N/ARecruiting

Video-Assisted Thoracoscopic Surgery

NCT07441902

N/ARecruiting

Liposomal Bupivacaine

NCT07458282

N/ARecruiting

Liposomal Bupivacaine

NCT07458295

PreclinicalRecruiting

Video-Assisted Thoracoscopic Surgery (VATS)

NCT07432711

Clinical

Trials by Indication[1]

Liposomal Bupivacaine3 trials

The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Laparoscopic Surgery

Recruiting·—·N/A·NCT07458256·190 enrolled

The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery

Recruiting·—·N/A·NCT07458282·318 enrolled

The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery in Gynecologic Oncology

Recruiting·—·N/A·NCT07458295·110 enrolled

Hemorrhoid1 trial

The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Hemorrhoid Surgery

Recruiting·—·N/A·NCT07442539·156 enrolled

Hip Arthroplasty1 trial

Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG)

Recruiting·HHuazhong University of Science and Technology·Phase 4·NCT06565910·60 enrolled

Video-Assisted Thoracoscopic Surgery1 trial

The Efficacy and Safety of Liposomal Bupivacaine for Rhomboid Intercostal Nerve Block in Relieving Postoperative Pain After Video-assisted Thoracoscopic Surgery

Recruiting·—·N/A·NCT07441902·134 enrolled

Video-assisted Thoracoscopic Surgery (VATS)1 trial

The Efficacy and Safety of Liposomal Bupivacaine Plus Bupivacaine Local Incisional Infiltration for Postoperative Pain in Patients Undergoing Video-assisted Thoracoscopic Surgery:A Multi-Center Randomized Controlled Trial

Recruiting·BBeijing Tiantan Hospital·Preclinical·NCT07432711·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Liposomal bupivacaine plus bupivacaine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Liposomal bupivacaine plus bupivacaine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Liposomal bupivacaine plus bupivacaine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Huazhong University of Science and Technology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHuazhong University of Science and Technology

Liposomal bupivacaine plus bupivacaine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Liposomal Bupivacaine3 trials

Hemorrhoid1 trial

Hip Arthroplasty1 trial

Video-Assisted Thoracoscopic Surgery1 trial

Video-assisted Thoracoscopic Surgery (VATS)1 trial

References

Drug Info

Quick Facts

Related News